sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
| Title: | sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma |
|---|---|
| Authors: | Katja Seipel, Naomi Porret, Gertrud Wiedemann, Barbara Jeker, Vera Ulrike Bacher, Thomas Pabst |
| Source: | Current Issues in Molecular Biology, Vol 44, Iss 4, Pp 1463-1471 (2022) |
| Publisher Information: | MDPI AG, 2022. |
| Publication Year: | 2022 |
| Collection: | LCC:Biology (General) |
| Subject Terms: | B-cell maturation antigen (BCMA), soluble BCMA (sBCMA), multiple myeloma (MM), anti-BCMA CAR-T cell therapy, Biology (General), QH301-705.5 |
| More Details: | BACKGROUND: Novel chimeric antigen receptor T-cells (CAR-T) target the B-cell maturation antigen (BCMA) expressed on multiple myeloma cells. Assays monitoring CAR-T cell expansion and treatment response are being implemented in clinical routine. METHODS: Plasma levels of soluble BCMA (sBCMA) and anti-BCMA CAR-T cell copy numbers were monitored in the blood, following CAR-T cell infusion in patients with relapsed multiple myeloma. sBCMA peptide concentration was determined in the plasma, applying a human BCMA/TNFRS17 ELISA. ddPCR was performed using probes targeting the intracellular signaling domains 4-1BB und CD3zeta of the anti-BCMA CAR-T construct. RESULTS: We report responses in the first five patients who received anti-BCMA CAR- T cell therapy at our center. Four patients achieved a complete remission (CR) in the bone marrow one month after CAR-T infusion, with three patients achieving stringent CR, determined by flow cytometry techniques. Anti-BCMA CAR-T cells were detectable in the peripheral blood for up to 300 days, with copy numbers peaking 7 to 14 days post-infusion. sBCMA plasma levels started declining one to ten days post infusion, reaching minimal levels 30 to 60 days post infusion, before rebounding to normal levels. CONCLUSIONS: Our data confirm a favorable response to treatment in four of the first five patients receiving anti-BCMA CAR-T at our hospital. Anti-BCMA CAR-T cell expansion seems to peak in the peripheral blood in a similar pattern compared to the CAR-T cell products already approved for lymphoma treatment. sBCMA plasma level may be a valid biomarker in assessing response to BCMA-targeting therapies in myeloma patients. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1467-3045 1467-3037 |
| Relation: | https://www.mdpi.com/1467-3045/44/4/98; https://doaj.org/toc/1467-3037; https://doaj.org/toc/1467-3045 |
| DOI: | 10.3390/cimb44040098 |
| Access URL: | https://doaj.org/article/184a772a47644dd891b18adfd9875798 |
| Accession Number: | edsdoj.184a772a47644dd891b18adfd9875798 |
| Database: | Directory of Open Access Journals |
| ISSN: | 14673045 14673037 |
|---|---|
| DOI: | 10.3390/cimb44040098 |
| Published in: | Current Issues in Molecular Biology |
| Language: | English |